Nautilus Biotechnology, Inc. (NAUT): Submission of Matters to a Vote of Security Holders
Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. naut-20260617 0001808805 FALSE 0001808805 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
How this was made
The 30-second read
Why it matters
Confirms governance and advisory vote results: Class II director elections, ratification of PricewaterhouseCoopers LLP as independent auditor for 2026, and advisory say-on-pay plus the frequency of future say-on-pay votes (1-year).
Market read
This is a governance/meeting-results disclosure with no new guidance, financing, or clinical/operational catalyst.
What to watch
The filing includes the chosen frequency for future say-on-pay votes (1-year), which may matter for governance-focused holders, but it is unlikely to drive trading without accompanying changes in compensation policy or performance metrics.
Background
The company submitted SEC Form 8-K (Item 5.07) reporting matters voted on at its 2026 annual meeting held June 17, 2026.
Ticker impact
Nautilus Biotechnology filed an 8-K detailing results of its June 17, 2026 annual meeting votes, including director elections and say-on-pay items.
Limited near-term impact; any reaction is likely muted unless investors were specifically focused on governance outcomes.
The filing is a standard Item 5.07 disclosure of vote tallies (board nominees, PwC ratification, say-on-pay and frequency). It does not introduce new strategy, financing, litigation, or clinical/financial datapoints.
Market effects
Minimal; governance vote results typically do not change biotech sector risk premia.
Minimal; US-listed microcap governance disclosure has limited spillover.
Minimal; no cross-border transaction or regulatory action described.
Counterpoint
If investors were concerned about board composition or executive compensation approval, the specific vote outcomes could reduce uncertainty marginally, but the filing still lacks new fundamentals.
Key entities
- companyNautilus Biotechnology, Inc.
US-listed biotech company filing Item 5.07 8-K with annual meeting vote results.
- auditorPricewaterhouseCoopers LLP
Independent registered public accounting firm appointment ratified for fiscal year ending Dec. 31, 2026.
